Kintsugi Funding & Investors

Kintsugi detects clinical depression and anxiety using machine learning and voice biomarkers. It provides talk therapy software to users in over 250 international cities, and as a result of collecting the world’s largest longitudinal, annotated voice data for machine learning, it has created the first clinical-grade voice biomarker diagnostic (U.S. Patent-Pending and FDA De Novo pending) to measure the severity of depression and anxiety in real-time.